Alliance for Clinical Trials in Oncology
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Clinical Trials
505
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (432 trials with phase data)β’ Click on a phase to view related trials
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Conditions
- Metastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Patient MonitoringProcedure: Bone ScanProcedure: PSMA PET ScanProcedure: MRIOther: Questionnaire Administration
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1524
- Registration Number
- NCT07200830
Family Communications After Genetic Testing
- Conditions
- Colon AdenocarcinomaColorectal AdenocarcinomaRectal AdenocarcinomaStage I Colon Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage I Rectal Cancer AJCC v8Stage II Colon Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage II Rectal Cancer AJCC v8Stage III Colon Cancer AJCC v8
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 4186
- Registration Number
- NCT07143487
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- Conditions
- Miscellaneous Neoplasm, NosNon-Neoplastic Condition, Nos
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 535
- Registration Number
- NCT07091617
Distance-Based Exercise to Preserve Function and Prevent Disability
- Conditions
- Hematopoietic and Lymphatic System NeoplasmLocalized Malignant Solid Neoplasm
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 104
- Registration Number
- NCT07059884
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Conditions
- Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
- Interventions
- Procedure: Biopsy of BladderProcedure: CystoscopyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Biospecimen CollectionProcedure: Transurethral Resection of Bladder Tumor
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 330
- Registration Number
- NCT07000084
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈBanner MD Anderson Cancer Center, Gilbert, Arizona, United States
πΊπΈUniversity of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 101
- Next
News
Dual Immunotherapy Combination Significantly Extends Survival in Advanced Cutaneous Squamous Cell Carcinoma
A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma.
Experts Debate Value of ctDNA Testing in Muscle-Invasive Bladder Cancer Management
Leading oncologists discuss the current limitations of circulating tumor DNA (ctDNA) testing in muscle-invasive bladder cancer, highlighting the need for more evidence before routine clinical implementation.
PROSPECT-Lung Trial Investigates Optimal Timing of Immunotherapy in Non-Small Cell Lung Cancer
The PROSPECT-Lung trial is evaluating whether immunotherapy is more effective when administered before or after surgery for resectable non-small cell lung cancer.
Veliparib Fails to Improve Survival in Glioblastoma Patients With MGMT Hypermethylation
A phase II/III trial evaluated the addition of veliparib to temozolomide in newly diagnosed glioblastoma patients with MGMT promoter hypermethylation.
myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS
myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).